Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated Thai children and adolescents with autism spectrum disorders

Journal of Clinical Psychopharmacology

Volumn 36, Issue 2, 2016, Pages 141-146

  Sukasem, Chonlaphat ^a   Hongkaew, Yaowaluck ^a   Ngamsamut, Nattawat ^b   Puangpetch, Apichaya ^a   Vanwong, Natchaya ^a   Chamnanphon, Montri ^a   Chamkrachchangpada, Bhunnada ^b   Sinrachatanant, Ananya ^b   Limsila, Penkhae ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

adolescent; autism spectrum disorders; children; CYP2D6; DRD2; prolactin; risperidone; Thai

Indexed keywords

CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; PROLACTIN; RISPERIDONE; DRD2 PROTEIN, HUMAN; GENETIC MARKER;

ADOLESCENT; ADULT; ARTICLE; AUTISM; CHEMILUMINESCENCE IMMUNOASSAY; CHILD; DRUG RESPONSE; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC MARKER; GENOTYPING TECHNIQUE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; THAI (PEOPLE); TREATMENT DURATION; AUTISM SPECTRUM DISORDER; BLOOD; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; GENETICS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; THAILAND; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; AUTISM SPECTRUM DISORDER; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC MARKERS; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLACTIN; RECEPTORS, DOPAMINE D2; RETROSPECTIVE STUDIES; RISPERIDONE; THAILAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957927538     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000474     Document Type: Article

References (31)

1. Douglas-Hall P, Curran S, Bird V, Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17. J Cent Nerv Syst Dis. 2011; 3: 143-153.
2. Hsia Y, Wong AY, Murphy DG, Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology (Berl). 2014; 231: 999-1009.
3. Scordo MG, Spina E, Facciolà G, Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999; 147: 300-305.
4. Correia CT, Almeida JP, Santos PE, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010; 10: 418-430.
5. Calarge CA, Ellingrod VL, Acion L, Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009; 19: 373-382.
6. Migliardi G, Spina E, D'Arrigo C, Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33: 1496-1501.
7. Knegtering R, Baselmans P, Castelein S, Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005; 162: 1010-1012.
8. Anderson GM, Scahill L, McCracken JT, Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007; 61: 545-550.
9. Masi G, Cosenza A, Mucci M,. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol. 2001; 11: 389-394.
10. Aklillu E, Kalow W, Endrenyi L, CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007; 17: 989-993.
11. Yasui-Furukori N, Saito M, Tsuchimine S, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 1491-1495.
12. de Leon J, Susce MT, Pan RM, The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005; 66: 15-27.
13. Roke Y, Van Harten PN, Franke B, The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet Genomics. 2013; 23: 487-493.
14. Torre DL, Falorni A,. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007; 3: 929-951.
15. Lopez-Rodriguez R, Roman M, Novalbos J, DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol. 2011; 31: 555-562.
16. Young RM, Lawford BR, Barnes M, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2∗A1 allele. Br J Psychiatry. 2004; 185: 147-151.
17. Thompson J, Thomas N, Singleton A, D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997; 7: 479-484.
18. Hongkaew Y, Ngamsamut N, Puangpetch A, Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone. Neuropsychiatr Dis Treat. 2015; 11: 191-196.
19. Roden DM, George AL Jr,. The genetic basis of variability in drug responses. Nat Rev Drug Discov. 2002; 1: 37-44.
20. Elmlinger MW, Kuhnel W, Ranke MB,. Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clin Chem Lab Med. 2002; 40: 1151-1160.
21. Guyda HJ, Friesen HG,. Serum prolactin levels in humans from birth to adult life. Pediatr Res. 1973; 7: 534-540.
22. Chamnanphon M, Pechatanan K, Sirachainan E, Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenomics Pers Med. 2013; 6: 37-48.
23. Rebsamen MC, Desmeules J, Daali Y, The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009; 9: 34-41.
24. Ozdemir V, Bertilsson L, Miura J, CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics. 2007; 17: 339-347.
25. Sukasem C, Sirachainan E, Chamnanphon M, Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev. 2012; 13: 4549-4553.
26. Schroth W, Goetz MP, Hamann U, Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009; 302: 1429-1436.
27. Barr CL, Kidd KK,. Population frequencies of the A1 allele at the dopamine D2 receptor locus. Biol Psychiatry. 1993; 34: 204-209.
28. Liu YZ, Tang BS, Yan XX, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur J Clin Pharmacol. 2009; 65: 679-683.
29. Barnard ND, Noble EP, Ritchie T, D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition. 2009; 25: 58-65.
30. Novalbos J, Lopez-Rodriguez R, Roman M, Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol. 2010; 30: 504-511.
31. Lidow MS, Goldman-Rakic PS,. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther. 1997; 283: 939-946.